OPEN-ACCESS PEER-REVIEWED
Dr Puneet Sudan1*, Mr. Pravin Nilkanth Bendle2, Dr. J. Lokeshwari3, Dr. Salam Himika Devi4, Dr. Kanu Shil5, Dr Navadha Bhatt6
1*Professor, Chandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri-Mohali 140307
2*Assistant Professor, N.G. Acharya and D.K. Marathe College Chembur, Mumbai, Maharashtra-400071
3*Associate Professor, Vels Medical College and Hospital, VISTAS Periyapalaya, Thiruvallur- 601102
4*Guest Faculty, Department of Zoology, Manipur University
5Assistant Professor, Faculty of Paramedical Sciences, Assam Downtown University, Guwahati-781026, Assam
6Assistant Professor, Department of Chemistry, Graphic Era Hill University, Dehradun
Abstract
With a view of getting necessary information on the metabolism of drugs and their assorted pharmacokinetics aspects, liquid chromatography-mass spectrometry has turned into an integral and very important technology. This review is a good one in the sense that it covers LC-MS applications in drug discovery, preclinical stages, clinical trials, and postmarketing surveillance. In the subsequent article, an account of LC-MS principles and their application as well as techniques of liquid chromatography and mass spectrometry about the identification and quantification of different metabolites and view of metabolic pathways are described. Improvements in LC-MS techniques including, high-resolution mass spectrometer (HRMS) and LC coupled with a tandem mass spectrometer (LC-MS/MS) have improved the methods of identifying metabolites through elements of sensitivity, accuracy, and efficiency. The update also presents such fresh developments as the hybrid systems on LC-MS-NMR hybrids and the application of radiolabeled compounds for distinguishing between metabolites. Furthermore, the use of LC-MS as well as the coupling of LC-MS with bioinformatics and machine learning for quick and detailed metabolite identification is also highlighted in the article. Therefore, through the analysis of such novel achievements, the review also highlights how LC-MS is instrumental in the manipulation and enhancement of drugs’ efficacy while monitoring the potential toxicity of drugs through the investigation of their metabolites and pharmacokinetic properties.
Keywords: Liquid Chromatography-Mass Spectrometry (LC-MS), Pharmacokinetics, High-Resolution
Mass Spectrometry (HRMS), Biotransformations, Proteomics, Metabolomics
References
[1]. Smith, D. A., & Obach, R. S. (2006). Metabolites and safety: What are the concerns, and how should we address them?. Chemical research in toxicology, 19(12), 1570-1579.
[2]. Di, L., & Obach, R. S. (2015). Addressing the challenges of low clearance in drug research. The AAPS journal, 17, 352-357.
[3]. Xie, C., Zhong, D., Yu, K., & Chen, X. (2012).Recent advances in metabolite identification and quantitative bioanalysis by LC–Q-TOF MS. Bioanalysis, 4(8), 937-959.
[4]. Zhang, D., Luo, G., Ding, X., & Lu, C. (2012).Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharmaceutica Sinica B, 2(6), 549-561.
[5]. Kaza, M., Karaźniewicz-Łada, M., Kosicka, K., Siemiątkowska, A., & Rudzki, P. J. (2019). Bioanalytical method validation: new FDA guidance vs. EMA guideline. Better or worse?. Journal of pharmaceutical and biomedical analysis, 165, 381-385.
[6]. Planz, V., Lehr, C. M., & Windbergs, M. (2016). In vitro models for evaluating the safety and efficacy of novel technologies for skin drug delivery. Journal of Controlled Release, 242, 89-104.
[7]. Lappin, G., & Stevens, L. (2008). Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opinion on Drug Metabolism & Toxicology, 4(8), 1021-1033.
[8]. Burt, T., Yoshida, K., Lappin, G., Vuong, L., John, C., De Wildt, S. N., … & Rowland, M. (2016). Microdosing and other phase 0 clinical trials: facilitating translation in drug development. Clinical and translational science, 9(2), 74.
[9]. Gritti, F., & Guiochon, G. (2013). Perspectives on the evolution of the column efficiency in liquid chromatography. Analytical chemistry, 85(6), 3017- 3035.
[10]. Swartz, M. E. (2005). UPLC™: an introduction and review. Journal of Liquid Chromatography & Related Technologies, 28(7-8), 1253-1263.
[11]. Snyder, L. R., Kirkland, J. J., & Dolan, J. W. (2011). Introduction to modern liquid chromatography. John Wiley & Sons.
[12]. Li, A. C., Shou, W. Z., Mai, T. T., & Jiang, X. Y. (2007). Complete profiling and characterization of in vitro nefazodone metabolites using two different tandem mass spectrometric platforms. Rapid Communications in Mass Spectrometry: An International Journal Devoted to the Rapid Dissemination of Up‐to‐the‐Minute Research in Mass Spectrometry, 21(24), 4001-4008.
[13]. Glish, G. L., & Burinsky, D. J. (2008). Hybrid mass spectrometers for tandem mass spectrometry. Journal of the American Society for Mass Spectrometry, 19, 161-172.
[14]. March, R. E. (1997). An introduction to quadrupole ion trap mass spectrometry. Journal of mass spectrometry, 32(4), 351-369.
[15]. Fenn, J. B., Mann, M., Meng, C. K., Wong, S. F., & Whitehouse, C. M. (1989). Electrospray ionization for mass spectrometry of large biomolecules. Science, 246(4926), 64-71.
[16]. Horning, E. C., Carroll, D. I., Dzidic, I., Lin, S. N., Stillwell, R. N., & Thenot, J. P. (1977). Atmospheric pressure ionization mass spectrometry: Studies of negative ion formation for detection and quantification purposes. Journal of Chromatography A, 142, 481-495.
[17]. Shah, V. P., Midha, K. K., Dighe, S., McGilveray, J., Skelly, J. P., Yacobi, A., … & Spector, S. (1992). Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. Journal of Pharmaceutical Sciences, 81(3), 309-312.
[18]. Gowda, G. N., & Djukovic, D. (2014). Overview of mass spectrometry-based metabolomics: opportunities and challenges. Mass Spectrometry in Metabolomics: Methods and Protocols, 3-12.
[19]. Prakash, C., Shaffer, C. L., & Nedderman, A. (2007). Analytical strategies for identifying drug metabolites. Mass spectrometry reviews, 26(3), 340- 369.
[20]. Zhang, B., Whiteaker, J. R., Hoofnagle, A. N., Baird, G. S., Rodland, K. D., & Paulovich, A. G. (2019). Clinical potential of mass spectrometry- based proteogenomics. Nature Reviews Clinical Oncology, 16(4), 256-268.
[21]. Stresser, D. M., Mao, J., Kenny, J. R., Jones, B. C., & Grime, K. (2014). Exploring concepts of in vitro time-dependent CYP inhibition assays. Expert opinion on drug metabolism & toxicology, 10(2), 157-174.
[22]. Rendic, S., & Guengerich, F. P. (2012). Contributions of human enzymes in carcinogen metabolism. Chemical research in toxicology, 25(7), 1316-1383.
[23]. Li, W., Zhang, J., & Francis, L. S. (Eds.). (2013). Handbook of LC-MS bioanalysis: best practices, experimental protocols, and regulations.
[24]. Niessen, W. M. A. (2003). Progress in liquid chromatography-mass spectrometry instrumentation and its impact on high- throughput screening. Journal of Chromatography A, 1000(1-2), 413-436.
[25]. Korfmacher, W. A. (2005). Foundation Review: Principles and applications of LC-MS in new drug discovery. Drug Discovery Today, 10(20), 1357-1367.
[26]. Xu, R. N., Fan, L., Rieser, M. J., & El-Shourbagy, T. A. (2007). Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. Journal of pharmaceutical and biomedical analysis, 44(2), 342-355.
[27]. Kumari Rayala, V. P., Kandula, J. S., & P, R. (2022). Advances and challenges in the pharmacokinetics and bioanalysis of chiral drugs. Chirality, 34(10), 1298-1310.
[28]. Rezende, V. M., Rivellis, A., Novaes, M. M. Y., de Alencar Fisher Chamone, D., & Bendit, I. (2013). Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug design, development, and therapy, 699-710.
[29]. Beccaria, M., & Cabooter, D. (2020). Current developments in LC-MS for pharmaceutical analysis. Analyst, 145(4), 1129-1157.
[30]. Grillo, M. P. (2015). Detecting reactive drug metabolites for reducing the potential for drug toxicity. Expert opinion on drug metabolism & toxicology, 11(8), 1281-1302.
[31]. Amacher, D. E. (2010). The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity. Toxicology and applied pharmacology, 245(1), 134-142.
[32]. Zheng, Y., Zhang, H., Liu, M., Li, G., Ma, S., Zhang, Z., … & Diao, X. (2022). Pharmacokinetics, mass balance, and metabolism of the novel urate transporter 1 inhibitor [14C] HR011303 in humans: metabolism is mediated predominantly by UDP-glucuronosyltransferase. Drug Metabolism and Disposition, 50(6), 798-808.
[33]. Wang, M., Xu, X. Y., Wang, H. M., Liu, M. Y., Chen, B. X., Jiang, M. T., … & Gao, X. M. (2022). A multi-dimensional liquid chromatography/high-resolution mass spectrometry approach combined with computational data processing for the comprehensive characterization of the multi- components from Cuscuta chinensis. Journal of Chromatography A, 1675, 463162.
[34]. Qi, K., Wu, L., Liu, C., & Pan, Y. (2021). Recent advances of ambient mass spectrometry imaging and its applications in lipid and metabolite analysis. Metabolites, 11(11), 780.
[35]. Chi, J., Shu, J., Li, M., Mudappathi, R., Jin, Y., Lewis, F., … & Gu, H. (2024). Artificial Intelligence in Metabolomics: A Current Review. TrAC Trends in Analytical Chemistry, 117852.
[36]. Hinson, J. A., Roberts, D. W., & James, L. P. (2010). Mechanisms of acetaminophen-induced liver necrosis. Adverse drug reactions, 369-405.
[37]. Peng, B., Lloyd, P., & Schran, H. (2005). Clinical pharmacokinetics of imatinib. Clinical pharmacokinetics, 44, 879-894.